{"id":52294,"date":"2025-08-25T11:06:37","date_gmt":"2025-08-25T09:06:37","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=presseberichte&#038;p=52294"},"modified":"2025-09-03T09:20:12","modified_gmt":"2025-09-03T07:20:12","slug":"royalty-pharma-acquires-licence-interest-for-amgens-imdelltra-maiwald-advises-on-transaction","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/en\/press-coverage\/royalty-pharma-acquires-licence-interest-for-amgens-imdelltra-maiwald-advises-on-transaction\/","title":{"rendered":"Royalty Pharma acquires licence interest for Amgen&#8217;s Imdelltra \u2013 Maiwald advises on transaction"},"content":{"rendered":"\n<p>Royalty Pharma has acquired a royalty interest in Amgen&#8217;s Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltra to Royalty Pharma for up to $65 million over the next 12 months.<\/p>\n\n\n\n<p>Imdelltra received accelerated approval from the U.S. FDA in May 2024 for patients with extensive-stage small cell lung cancer (ES-SCLC) who relapsed after platinum-based chemotherapy. ES-SCLC affects around 360,000 people worldwide every year and has a poor prognosis: median survival is about 12 months, and the five-year survival rate is just 7%.<\/p>\n\n\n\n<p>Royalty Pharma sees the transaction as a strategic step to further diversify its portfolio and strengthen long-term growth. BeOne Medicines aims to use the monetization of the royalty interest to increase financial stability and gain more flexibility in further developing innovative oncology products.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-to-acquire-royalty-interest-in-amgens-imdelltra-for-up-to-950-million\/\" data-type=\"link\" data-id=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-to-acquire-royalty-interest-in-amgens-imdelltra-for-up-to-950-million\/\" target=\"_blank\" rel=\"noopener\">Click here to red the full article.<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-52294","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/52294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":2,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/52294\/revisions"}],"predecessor-version":[{"id":52300,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/52294\/revisions\/52300"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/media?parent=52294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}